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Hop, an essential ingredient in most beers, contains a number of prenylflavonoids, among which
8-prenylnaringenin (8-PN) would be the most potent phytoestrogen currently known. Although a
number of health effects are attributed to these compounds, only a few reports are available about
the bioavailability of prenylflavonoids and the transformation potency of the intestinal microbial
community. To test these transformations, four fecal samples were incubated with xanthohumol,
isoxanthohumol (IX), and 8-PN. Upon incubation with IX, present in strong ales up to 4 mg/L, 36%
was converted into 8-PN in one fecal sample and the estrogenic properties of the sample drastically
increased. In an experiment with 12 fecal cultures, this conversion was observed in one-third of the
samples, indicating the importance of interindividual variability in the intestinal microbial community.
Eubacterium limosum was identified to be capable of this conversion (O-demethylation) of IX into
8-PN, and after strain selection, a conversion efficiency of 90% was achieved. Finally, strain
supplementation to a nonconverting fecal sample led to rapid and high 8-PN production at only 1%
(v/v) addition. Up to now, the concentration of 8-PN in beer was considered too low to affect human
health. However, these results show that the activity of the intestinal microbial community could more
than 10-fold increase the exposure concentration. Because prenylflavonoids are present in many
beers with IX being the major constituent, the results raise the question whether moderate beer
consumption might contribute to increased in vivo levels of 8-PN and even influence human health.
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INTRODUCTION
Hops (Humulus lupulus L.) have been used for centuries as
an essential raw material in beer brewing providing bitterness
and flavor to beer. In the past few years, the plant has gained
increasing attention as a source of prenylflavonoids, a subclass
of polyphenols. These are present in the lupulin glands, found
in the female hop cones. In this group, two prenylchalcones,
xanthohumol (X) and desmethylxanthohumol (DMX), and three
prenylflavanones, isoxanthohumol (IX), 8-prenylnaringenin (8-
PN), and 6-prenylnaringenin (6-PN) (Figure 1), now receive
much attention because of their possible health-promoting
properties. X has been identified as a strong cancer chemopre-
ventive agent (1), while 8-PN has been shown to be one of the
most potent phytoestrogens identified so far, with a considerably
higher activity than the well-known soy phytoestrogens (2, 3).
These interesting properties have led to intense research aiming
at deciphering various bioactivities. 8-PN showed in vivo
estrogenic activity (4, 5), prevented bone loss in rats (6),
inhibited angiogenesis (7) and metastasis (8), and exhibited
antiandrogenic activity (9).
There is considerable interest in whether human exposure to
phytoestrogens has either health risks or benefits (10-12). In
the case of hop prenylflavonoids, beer is the main dietary source,
with an estimated daily intake of about 0.14 mg prenylflavonoids
(13). However, the concentrations detected in beer (and,
therefore, the average intake) significantly depend on the
brewing process, as strong ales contain up to 4 mg/L. Although
X is present as a predominant prenylchalcone [up to 1% (m/
m)] (14), most of it is transformed into IX by thermal
isomerization during wort boiling. As a result, IX is the major
prenylflavonoid found in beer in concentrations from 500 íg/L
(lager/pilsner) up to 4 mg/L (strong ale) (13, 15). DMX is
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equally converted into 8-PN giving final concentrations in beer
up to 100 íg 8-PN/L and IX vs 8-PN ratios between 20 and
40. However, despite the high activity of 8-PN, the total
estrogenicity of beers is still 500-1000-fold lower than the
concentration needed for harmful in vivo activity (100 mg/
L) in rat experiments (4). Moreover, many beers are now made
using hop extracts instead of whole hops, giving lower
concentrations of 8-PN or even no 8-PN. Therefore, it is
generally agreed that with the current knowledge, no detrimental
health effects due to estrogens in beer are to be expected through
moderate beer consumption (2, 4, 16). Besides beer, a number
of hop-based dietary supplements are marketed, but contents
may vary (17).
To exert in vivo effects claimed in vitro, dietary flavonoids
need to be absorbed from the gut and reach their targets
unchanged. However, up to now, no peer-reviewed data with
regard to the bioavailability of prenylflavonoids are available.
In general, monomeric flavonoids reach the small intestine
unchanged (18), where absorption from the gut in the mesenteric
circulation can take place. In vitro studies indicated extensive
liver biotransformation of X (19, 20), IX (21), and 8-PN (22)
upon absorption. However, the extent of dietary polyphenol
absorption in the small intestine is rather limited (10-20%) (23,
24), thereby implying that a large proportion reaches the colon.
Naringenin, the nonprenylated analogue of 8-PN, showed
intensive microbial biotransformation in the intestine, including
ring cleavage and dehydroxylation (25), followed by absorption
and urinary excretion (26). The extent of degradation strongly
depended on compound concentration and individual composi-
tion of the gut microbiota of the different human subjects. On
the other hand, when X was fed to rats, it was mainly recovered
in unchanged form from the feces (89%) (27).
As a source of 8-PN, IX, and X, moderate beer consumption
leads to the intake of bioactive compounds, which could either
act beneficially or be harmful depending on the final concentra-
tion reaching the target organs in the human body. In many
cases, the bioavailability of phytoestrogens is strongly influenced
by the composition and activity of the gut microbial community
(28-30). As the microbiota can activate as well as degrade these
components, the focus of the present study is to investigate the
role of the microbial community toward the in vivo estrogenic
properties of beer or food supplements containing hops by
investigating the biotransformation or the breakdown of X, IX,
and 8-PN in fecal cultures and to evaluate interindividual
differences. Understanding these processes is a crucial step
toward the estimation of the final bioactivity of dietary
flavonoids derived from hops and the evaluation of possible
effects associated with such intake.
MATERIALS AND METHODS
Chemicals. X was isolated from spent hops (i.e., the residue that
remains after liquid or supercritical carbon dioxide extraction of hop
cones, NateCO2, Wolnzach, Germany) via methanol/ethyl acetate (9/
1, v/v) extraction, flash chromatography fractionation, and purification
by semipreparative chromatography on a Varian Omnisphere C-18
column (250 mm  21.4 mm, 10 ím, Varian, St.-Katelijne-Waver,
Belgium) using a Gilson 322 Pump (Gilson, Middleton, United States)
with a Gilson UV-vis 156 detector and a Gilson 206 Fraction Collector.
IX was prepared from X by isomerization under reflux in a 5% ethanolic
KOH solution. IX was purified from the reaction mixture by semi-
preparative high-performance liquid chromatography (HPLC). 8-PN was
prepared by prenylation of naringenin with 2-methylbut-3-en-2-ol in
dioxane in the presence of boron trifluoride (31). All chemicals were
obtained from Sigma-Aldrich (Bornem, Belgium). Using semiprepara-
tive HPLC, 8-PN was purified from a fraction resulting from flash
chromatography containing both 8-PN and 6-PN and a B ring prenylated
naringenin. The identities of X, IX, and 8-PN were confirmed by
comparison of 1H NMR and 13C NMR data (Varian 300 MHz) with
literature values (32), and the purities were assessed to be more than
99% by HPLC.
Fermentation Conditions. Bacterial Cultures. Fecal samples were
obtained from 12 healthy subjects between the ages of 20 and 35 and
designated A-L. None of the subjects had a history of gastrointestinal
disease and had not taken antibiotics during 3 months prior to sample
delivery. Fecal slurries of 20% (w/v) fresh fecal samples were prepared
by homogenizing the feces with phosphate-buffered saline (0.1 M, pH
7) containing 1 g/L sodiumthioglycolate as a reducing agent. The
particulate material was removed by centrifugation (1 min, 500g).
Eubacterium limosum DSM 20543 was obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany).
Culture Medium. All fermentation experiments were performed in
brain heart infusion broth (37 g/L, Oxoid, Hampshire, United Kingdom)
with 0.5 g/L L-cystein HCl. Fecal bacteria as well as E. limosum require
Figure 1. Structures of hop prenylflavonoids. By thermal isomerization, the chalcones X and DMX are converted into the respective flavanones IX (from
X) and 8-PN and 6-PN (from DMX).
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anaerobic conditions (low redox potential) for growth. Therefore,
resazurin (2 mg/L) was added as a redox indicator. A pink color
indicated a high redox potential (>-80 mV), and a colorless solution
showed a low redox potential (<-80 mV), i.e., anaerobic. The redox
potential in the large intestine typically ranged between -150 and -280
mV. The medium was autoclaved at 121 °C for 15 min.
Prior to addition to the autoclaved growth medium in the fermenta-
tion vessels, stock solutions of the different prenylflavonoids (X, IX,
and 8-PN) were prepared in dimethyl sulfoxide (DMSO) in a
concentration of 5 g/L. Changing the solvent from DMSO to ethanol
did not influence the outcome of the experiments (data not shown).
Fermentation. The fermentation volume was either 25 or 50 mL. In
the case of the fecal fermentation experiments, each batch culture
consisted of 90% brain heart infusion medium, 10% fecal slurry, and
25 mg/L of X, IX, or 8-PN (5 íL stock solution/mL batch culture).
Culture experiments with E. limosum were performed by adding 100
íL of bacterial stock to the brain heart infusion medium and 25 mg/L
of X, IX, or 8-PN (5 íL stock solution/mL batch culture). Each batch
was sealed with rubber tops, and anaerobiosis was obtained by flushing
the flasks with N2 during 20 cycli of 2 min at 700 mbar overpressure
and 900 mbar underpressure. Cultures were incubated at 37 °C on a
shaker for the duration of the experiment. At given time points, samples
were taken using syringes. All experiments were performed in triplicate.
Prior to the start of the experiment, all fecal samples were tested for
background concentrations of prenylflavonoids that could be present
in the sample itself, but none were detected.
Chemical Analysis. Extraction Protocol. Two extraction procedures
were compared to reach the best recovery of prenylflavonoids from
fecal cultures: solid phase extraction using Bond Elut C18 silica
columns (3 mL, 200 mg, Varian) and liquid/liquid extraction with ethyl
acetate. The latter protocol gave the best results with recoveries of
>90% for X, IX, and 8-PN, and it was further optimized. Samples
originating from fecal cultures were diluted 5-fold in acidified H2O
(pH 2) prior to extraction. Samples from E. limosum incubations were
used as such. A 1 mL sample was added to 4 mL of acidified H2O (pH
2) and 5 mL of ethyl acetate in test tubes. After they were rigorously
vortexed, the samples were centrifuged at 3000g for 10 min. Three
milliliters of the ethyl-acetate phase was transferred to a new test tube
and dried under N2 stream. Finally, the extracts were dissolved in
exactly 500 íL of methanol, transferred into HPLC vials, and stored
at -20 °C prior to analysis.
High-Performance Liquid Chromatorgaphy (HPLC) Analysis. Quan-
titative analyses were effected by HPLC using a Waters 2695 Alliance
Separations Module (Waters, Milford, United States) equipped with a
Waters 996 Photodiode Array Detector and Waters Millenium Software
v3.20. A C18 reversed phase column (Varian, Omnisphere, 250 mm
 4.6 mm, 5 ím) was used in combination with a gradient composed
of solvent A [water acidified with 0.025% (v/v) formic acid] and solvent
B [methanol acidified with 0.025% (v/v) formic acid]. Gradient
profile: 0-3 min, 45% B in A; 3-32 min, from 45% B in A to 95%
B in A; 32-37 min, 95% B in A; 37-45 min, 95% B in A to 45% B
in A; 45-47 min, 45% B in A. The sample size was 20 íL, the flow
rate was 1 mL/min, and the column temperature was 35 °C. Detection
was done simultaneously at 295 nm (for IX, 8-PN, and 6-PN) and at
370 nm (for X) using diode array detection. Peaks were identified by
comparison of the retention times with those of authentic isolated
reference compounds, as well as by inspection of the respective UV
spectra. External five-point calibration curves were established for X,
IX, 8-PN, and 6-PN (R2 > 0.999). Concentrations were calculated based
on peak area integration. An extra confirmation of the identity of the
compounds in the samples was achieved based on the typical
fragmentation patterns in liquid chromatography-mass spectrometry/
mass spectrometry (LC-MS/MS) analysis using a Waters Quattro micro
with electrospray ionization (32).
In Vitro Estrogenicity Testing. To test the estrogenic activity of
the prenylflavonoids and their metabolites, we used a modified protocol
from De Boever et al. (33) that was based on the protocol developed
by Routledge and Sumpter (34) for the yeast estrogen bioassay. In brief,
Saccharomyces cereVisiae was transformed with the human estrogen
receptor (ERR) gene, together with expression plasmids containing
responsive elements and the lacZ reporter gene (encoding the enzyme
â-galactosidase). The estrogenic activity of the samples was expressed
as percentage equivalence to 10 nM 17â-estradiol (E2), which elicited
a 100% response in the estrogen receptor bioassay. The bioassays were
performed in 96 well plates in which 10 íL of the test compounds
was incubated with 240 íL of the genetically modified yeast (absor-
bance of 0.25 at 610 nm). Serial dilutions of the test compounds were
made in DMSO, which allowed generating dose-response curves for
dose (ordinate) vs activity (abscissa). The data were fitted by a four-
parametric logistic model using the Marquardt-Levenberg algorithm
(Sigmaplot 4.0, SPSS, Chicago, IL) (33).
RESULTS
Biotransformation of Hop Prenylflavonoids. Incubation of
X, IX, and 8-PN with Human Fecal Samples. The capacity of
the cultures obtained from fecal samples A, B, C, and D (further
referred to as cultures A-D) to degrade or transform the hop
prenylflavonoids X, IX, and 8-PN was tested by incubating the
cultures with 25 mg/L of each individual compound for a period
of 8 days. Results are presented as molar % recovery of X, IX,
or 8-PN, relative to the dosed amount (Table 1). X proved to
be relatively stable with a recovery of above 65%. In all cultures
incubated with X, IX was detected (few %). However, as this
was also observed after incubation of autoclaved fecal material
with X (data not shown), no bacterial mechanisms are involved
in the isomerization of X into IX. In culture C, also 5% of 8-PN
was recovered. In cultures A, B, and D, IX was very resistant
to transformation as more than 80% was recovered. In culture
C, however, the bacterial community was able to transform IX
into 8-PN, as IX strongly disappeared and about 35% of 8-PN
was recovered. This transformation did not occur when testing
autoclaved fecal material. Remarkably, 90% of the initial amount
of 8-PN was degraded in cultures A and D, while more than
50% of 8-PN was still recovered in cultures B and C. These
results indicate that different fecal cultures are characterized
by varying capacities to transform the hop prenylflavonoids.
Microbial ConVersion of IX into 8-PN by Fecal Cultures.
The most interesting data obtained from Table 1 are the results
from culture C. A considerable amount of IX was transformed
into 8-PN, showing the role of IX as a pro-estrogen, which can
Table 1. Microbial Transformation of X, IX, and 8-PN after Incubation with Fecal Samples A−Da
% recovery
X IX 8-PN
start X IX 8-PN X IX 8-PN X IX 8-PN
A 74.9 (10.7) 5.9 (0.8) NDb ND 90.1 (6.3) ND ND ND 11.2 (0.5)
B 80.5 (2.5) 9.1 (2.4) ND ND 83.0 (5.1) ND ND ND 67.2 (13.1)
C 73.6 (3.1) 2.2 (0.1) 5.3 (0.2) ND 19.0 (2.9) 36.4 (7.4) ND ND 54.6 (2.7)
D 65.4 (4.2) 11.7 (1.6) ND ND 86.0 (4.5) ND ND ND 7.6 (1.3)
a The compounds were incubated for 8 days at a concentration of 25 mg/L, and results are presented as average (+ SD) molar percentage recovery of X, IX, or 8-PN
relative to the dosed amount of flavonoid. b ND, not detected.
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be activated by the intestinal microbial community. To further
investigate these transformations, cultures E-L were incubated
with 25 mg/L IX and samples were taken after 72 h (Figure
2). In cultures E, J, and K, varying amounts of 8-PN were
recovered, and especially in cultures J and K, a lower recovery
of IX was found in comparison to the non-8-PN-producing
cultures. These results stress the significance of the difference
in microbial community composition and activity, since conver-
sion of IX into 8-PN was evident in only four of 12 cultures.
In Vitro Estrogenic Response of the Incubations. As 8-PN is
known to have strong estrogenic activity, the conversion of IX
into 8-PN and the degradation of 8-PN were monitored by
measuring the estrogenic response of the incubations of cultures
A-D with IX and 8-PN at time zero and after 8 days (Figure
3). As no increase of the estrogenic response was detected for
the cultures A, B, and D upon incubation with IX, data are not
shown. In contrast, the high estrogenic activity was determined
in culture C, strongly indicating transformation of IX into an
estrogenically active reaction product. The estrogenic response
of all cultures incubated with 8-PN decreased after the incuba-
tion because the dose-response curve shifted to higher con-
centrations. This suggests the degradation of 8-PN into non-
estrogenic derivatives. The strongest decrease was seen in
culture A as the EC50 value rose from 120 to 800 nM. The
lowest decrease was seen for culture B, while for cultures C
and D a shift of 0.5 log units of the EC50 values was detected.
As HPLC analysis showed that more than 90% of the initially
dosed 8-PN disappeared in culture D, a more pronounced shift
in estrogenic activity was expected for this sample. Therefore,
the higher remaining activity could be due to other degradation
products with estrogenic activity. This will be investigated in
further research. In this experiment, 8-PN was 25-fold less active
than E2 based on their EC50 values.
Incubation of X, IX, and 8-PN with E. limosum. As E.
limosum is an intestinal bacterium capable of O-demethylation
and degradation of flavonoids, this species was tested for its
capacity to transform or degrade X, IX, or 8-PN. To investigate
long-term stability, the bacterium was incubated with 25 mg/L
Figure 2. Transformation of IX by human fecal cultures. Samples E−L
were incubated with 25 mg/L IX for 3 days. Results are presented as
average (+ SD) concentrations of IX and 8-PN recovered (n ) 3). When
no bars are displayed, no 8-PN was detected.
Figure 3. Average (+ SD) estrogen response of 8-PN-incubated fecal samples A, B, C, and D and of IX-incubated fecal sample C, as measured at day
0 and after 8 days of incubation. The estrogen responses of 8-PN and E2 are also shown (n ) 3).
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of each compound for a period of 13 days. Results are presented
as molar % recovery of X, IX, or 8-PN, relative to the dosed
amount of individual compound (Table 2). Again, conversion
of X into IX was a spontaneous process, as similar results were
obtained with autoclaved bacterial cultures. E. limosum was able
to transform IX into 8-PN, but because incubated 8-PN could
almost fully be recovered after 13 days, further degradation did
not occur. The small proportion of 6-PN recovered is probably
due to isomerization of 8-PN via DMX as an intermediate.
Production of 8-PN by E. limosum. Transformation Kinet-
ics. To investigate the transformation kinetics of the conversion
of IX into 8-PN, the same E. limosum was incubated with IX
in three parallel experiments and the concentrations of IX and
8-PN were monitored for a period of 13 days (Figure 4).
Although incubation conditions were nearly identical, the 8-PN
production already started after 3 days in incubation 3, while a
very long lag phase (10 days) was noted in incubations 1 and
2. Moreover, the transformation rate was higher in incubation
1 than in incubation 2. This shows that transformation kinetics
differed depending on the grown E. limosum culture.
Strain Selection. Because of the differences in transformation
rate, it was attempted to select the most efficient IX-converting
strain performing three successive selection rounds. This
consisted of six parallel incubations of E. limosum with 25 mg/L
IX and incubation for 8 days. Next, the culture that produced
the highest amount of 8-PN was selected and used as inoculum
for the next round of six parallel incubations (Table 3). While
in the first selection round, the lowest production was only 2%,
an increase of up to 82% was apparent after three selection steps,
and the most efficient culture transformed all of the dosed IX
into 8-PN. The mean production of all six incubations in each
round increased from 22.5 up to 90.5%, and the standard
deviation (SD) decreased from 20 to 7% after the selection
procedure. This means that, after only three rounds, a strain
was selected, which converted almost all IX (high mean) and
was also stable (low SD).
E. limosum Supplementation to Fecal Cultures. From Table
1 and Figure 2, it was concluded that interindividual differences
ultimately determined the capacity to transform IX into 8-PN.
Therefore, we supplemented the most efficient E. limosum strain
from the selection experiments to the nonproducing culture B
to examine the capacity of this strain to start up production of
8-PN in the complex environment of an intestinal suspension.
The strain was added to the culture in proportions ranging from
0 up to 100%. The mixture was incubated with IX for a period
of 7 days (Table 4), and the concentration of 8-PN was
monitored every other day. The results show that, with increas-
ing supplementation of E. limosum, the production of 8-PN
increased. The pure E. limosum culture gave a 100% conversion
of IX into 8-PN, but even at 1% supplementation, half of the
dosed IX was already transformed into 8-PN after only 1 day.
Remarkably, a maximum concentration of 8-PN was reached
for all incubations on the first day, which indicates that all of
the available IX was immediately converted. No further
transformation of 8-PN was detected as the concentrations of
8-PN at days 1 and 7 were not significantly different (Student’s
T-test, p > 0.05).
DISCUSSION
In this study, the conversion of hop prenylflavonoids by
human intestinal microbiota was investigated. These plant-
derived compounds are considered as one of the four principal
groups of phytoestrogens in food and are mainly ingested
through beer consumption. Because 8-PN concentrations in beer
are generally very low, possible health effects due to exposure
Table 2. Transformation of X, IX, and 8-PN by E. limosuma
E. limosum
% recovery
start X IX 8-PN 6-PN
X 85.0 (2.6) 16.9 (3.5) NDb ND
IX ND 51.4 (4.6) 36.4 (11.6) ND
8-PN ND ND 98.3 (1.0) 0.4 (0.1)
a The compounds were incubated for 13 days at a concentration of 25 mg/L,
and results are presented as averagea (+ SD) molar percentage recovery of X,
IX, 8-PN, or 6-PN. b ND, not detected.
Figure 4. Three parallel incubations of E. limosum with 25 mg/L IX. The
disappearance of IX (black symbols) and production of 8-PN (white
symbols) were monitored over a period of 13 days.
Table 3. Selection of 8-PN Producing E. limosum by Three Repeated
Incubationsa
molar % IX w 8-PN conversion
I II III
lowest 2.1 24.3 82.1
highest 46.5 79.4 102.5
mean 22.5 57.9 90.5
SD 19.3 19.6 6.9
a Six strains were incubated for 8 days with 25 mg/L IX, and the best IX
converting strain was used for the next selection round. Lowest and highest 8-PN
production as well as mean (+ SD) for each selection round are listed.
Table 4. Supplementation of E. limosum to Culture B in Different
Proportions Ranging from 0% (Solely Fecal Sample) up to 100%
(Axenic E. limosum Culture) and Incubation with 90 íM IX (n ) 3)a
time (days)
0 1 3 5 7
% suppl. 8-PN production (íM)
0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
1 0.0 (0.0) 49.0 (3.1) 36.8 (8.3) 48.1 (14.0) 46.4 (8.9)
5 0.0 (0.0) 41.1 (12.6) 38.9 (14.7) 40.1 (10.2) 37.3 (10.6)
25 0.0 (0.0) 38.7 (7.4) 36.8 (4.3) 38.5 (20.6) 31.6 (10.7)
50 0.0 (0.0) 76.2 (20.2) 61.2 (9.5) 59.2 (21.6) 50.1 (16.9)
75 0.0 (0.0) 74.0 (18.6) 63.2 (15.5) 60.4 (14.1) 60.4 (13.8)
100 0.0 (0.0) 88.5 (3.8) 74.7 (6.8) 83.7 (18.4) 75.7 (2.7)
a Results are presented as average (+ SD) 8-PN production. As culture B did
not convert IX into 8-PN, the 8-PN production was linked to the supplemented
strain. The nonconverted IX remained present as unchanged component throughout
the incubation period.
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to these substances are usually considered negligible. However,
this view could change when considering that IX, which is
quantitatively the most important prenylflavonoid in beer, may
act as a pro-estrogen in food due to microbial O-demethylation.
This could lead to enhanced concentrations of 8-PN and to a
possibly important exposure after beer consumption. However,
there seem to be important interindividual differences, as only
one-third of the tested human fecal samples showed IX
activation. The intestinal bacterium E. limosum was able to
perform this conversion, and after strain selection, the bacterium
rapidly converted all IX into 8-PN. Strain supplementation to
nonconverting fecal samples led to rapid and efficient 8-PN
production, even at low ratios.
The possibility that IX would act as a pro-estrogen was
recently detected in vivo by Schaefer et al. (35). After dosing
10 mg of IX to two men, increased 8-PN concentrations,
corresponding to up to 5% conversion, were detected in urinary
samples. According to the authors, this in vivo activation would
be an oxidative demethylation process in the liver, based on
the findings of Nikolic et al. (21). Although the prenyl chain of
IX was the primary target of liver modifications, the latter
researchers also recovered small amounts of 8-PN after the
incubation of IX with liver microsomes. This contradicts with
the findings of Coldham et al. (36) who could not find IX
activation by the liver. However, the liver is not the only
transformation site inside the human body. The human colon
contains 1012 microorganisms/cm3, with an enormous meta-
bolic potential. Bacterial enzymes may catalyze many reactions
including hydrolysis, dehydroxylation, demethylation, ring
cleavage, and decarboxylation. The importance of this microbial
community in the metabolism of phytoestrogens has been clearly
established. Decroos et al. (37) recently isolated a microbial
consortium capable of transforming the soy phytoestrogen
daidzein into equol, and Wang et al. (38) found two bacteria
responsible for the conversion of lignans. Moreover, several
intestinal bacteria possess â-glucosidases, which are necessary
for the hydrolysis of phytoestrogen glucosides (30). Therefore,
the gut microbiota are now considered as an important factor
influencing phytoestrogen bioavailability (29).
Our results confirm a similar activity related to the group of
prenylflavonoids, since IX can be converted into the potent
phytoestrogen 8-PN. These transformation products can sub-
sequently be absorbed from the colon, as it is established for
soy isoflavones (39), to exert biological activity inside the body.
While 8-PN was only one out of a large number of liver
transformation products of IX (21), the human intestinal
microbiota selectively converted IX into 8-PN with high
conversion efficiencies (>35%). These results show that the
impact of microbial activities on in vivo conversion of IX will
most likely be more pronounced than possible liver transforma-
tions. However, as only one-third of the samples converted IX,
interindividual variability in microbial community activity could
strongly influence this in vivo conversion. Finally, Schaefer et
al. (35) noted that urinary 8-PN excretion after beer consumption
was slower than expected (up to several days), which could
very well be due to delayed conversion of IX into 8-PN in the
intestine, followed by absorption and renal excretion. Entero-
hepatic circulation is another important factor determining the
retention of IX and 8-PN.
Up to now, little is known about intestinal transformations
of prenylflavonoids. Nookandeh et al. (27) dosed 1000 mg X/kg
body weight to rats and isolated 22 metabolites from the feces.
The majority (89%) of the recovered flavonoids was unchanged
X, which is in agreement with our data, as we detected only
very minor degradation of X. The rest was composed of small
amounts of different metabolites including some IX. Avula et
al. (40) performed a similar experiment with rats and detected
mainly unchanged X next to a number of unidentified metabo-
lites. However, no published data were available with regard
to the availability of IX and 8-PN to gut microbiota. In our
experiments with fecal samples, IX was either partially trans-
formed into 8-PN or remained very stable during the incubations.
8-PN, on the other hand, was more sensitive to degradation as,
in some experiments, 90% of the dosed amount disappeared.
One possible explanation for this difference in stability between
IX and 8-PN is the protective effect of the methoxy group on
the A ring of IX, as this is the only structural difference with
8-PN. In general, the first step in the degradation of flavonoids
is the opening and scission of the heterocyclic ring (41) and
the absence of a free hydroxyl in positions 5, 7, or 4′ would
protect the compound from this cleavage (42, 43). An important
consequence regarding optimum bioavailability could be a slow
release of 8-PN from IX in the colon and absorption through
the gut epithelium, taking into account that 8-PN is prone to
undergo decomposition.
To identify possible microbial degradation pathways of
prenylflavonoids, a comparison can be made with naringenin,
lacking the prenyl side chain. This flavanone has been exten-
sively studied and is mainly present in citrus fruits in a
glycosidic form (44) and in tomatoes as aglycone (45).
Degradation of naringenin by intestinal bacteria starts with
heterocyclic ring cleavage, followed by dehydroxylation yielding
phloroglucinol and 3-phenylpropionic acid (25). The extent of
this degradation strongly depended on the nature of the fecal
sample, which resembles the results obtained after the incubation
of the fecal samples with 8-PN. This again shows that
interindividual differences in the microbial community of the
intestine are decisive on the fate of 8-PN and related flavonoids
in the human body.
Microbial O-demethylation (8-PN from IX) is known for a
number of anaerobic bacteria that can even use methyl ethers
for respiratory growth. These bacteria either use fumarate
(Desulfitobacterium) as an electron acceptor (46) or are so-called
homoacetogens converting CO2 into acetate (47). E. limosum
is a homoacetogenic bacterium, which is frequently isolated from
human feces (48). It is known to be involved in the biotrans-
formation of specific isoflavonoids (49), and a related Eubac-
terium strain was identified as a producer of the lignan enterodiol
(38). Instead of trying to isolate a bacterium with the ability to
demethylate IX into 8-PN, we investigated the activity of this
E. limosum. The strain proved to be able to produce 8-PN and
did not further degrade it, as this compound could be completely
recovered following the incubation of E. limosum with 8-PN.
After strain selection, the bacterium even quantitatively con-
verted IX into 8-PN after only 1 day of incubation. Because IX
can easily be produced from X, a microbial fermentation process
of IX could facilitate efficient large scale production of 8-PN.
On the other hand, strain supplementation to a nonconverting
fecal sample led to rapid and high IX conversion. This could
imply that cosupplementation of IX and a transforming bacte-
rium leads to a “slow release” 8-PN production in situ in the
intestine, after which the produced 8-PN can be absorbed and
transported to its targets.
Several reports now correlate possible health benefits with
intentional phytoestrogen uptake (10). Yet, at the same time,
questions rise whether environmental exposure to phytoestrogens
could impose health risks such as endocrine disruption. More-
over, overall health effects may result from a combination of
6286 J. Agric. Food Chem., Vol. 53, No. 16, 2005 Possemiers et al.
phytochemicals with multiple and perhaps additive or interfering
activities. Up to now, only isoflavones and lignans are consid-
ered relevant phytoestrogens in the human diet (10), especially
because 8-PN concentrations in beer are considered to be too
low for positive or negative health effects (4, 16). However,
the intestinal microbial community may have a crucial role in
the in vivo conversion of IX into 8-PN. Ultralow dose estrogen
therapy at a dose of only 0.25 mg E2 per day over a period of
3 years significantly improved bone density as compared with
placebo without significant effects on endometrial thickness (50).
According to our results, in some humans, at least 35% of the
ingested IX may be converted into 8-PN. Taking into account
an accumulation factor of 2 based on slow elimination of 8-PN
(35), a daily consumption of 1 L of beer containing 2 mg IX/L
would lead to a daily 8-PN burden of 1.4 mg. As 8-PN is only
about 10 times less active as compared to E2, the daily exposure
of about 0.14 mg E2 equivalents is well within the range of
positive biological activity (e.g., protective effect on bone
metabolism) without negative side effects (e.g., proliferation of
the endometrium). Although this example is very simplified and
does not account for differences in bioavailability, it clearly
indicates the intriguing role of the gut microbial community in
the exposure to biologically active compounds. As microbial
O-demethylation of IX could readily lead to a 10-fold increase
of the ingested 8-PN, supposing an IX vs 8-PN ratio in beer of
30 (13), large population studies are warranted in order to
acquire insight into the in vivo bioavailability of hop prenylfla-
vonoids throughout the intestine and the extent of microbial
transformations in the colon. Such studies are essential to
validate our findings on the capacity of individuals to produce
8-PN from IX, giving rise to possible health effects of IX
consumption.
ABBREVIATIONS
8-PN, 8-prenylnaringenin; IX, isoxanthohumol; X, xantho-
humol; DMX, desmethylxanthohumol; HPLC, high-performance
liquid chromatography; E2, 17â-estradiol; LC-MS/MS, liquid
chromatography-mass spectrometry/mass spectrometry.
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